Merck & Co., which has been seeking U.S. approval for a successor to its withdrawn arthritis painkiller Vioxx for nearly three years, says it has given regulators new patient data about the drug and expects a decision by April.

Also, the drug maker has disclosed that a Canadian court has authorized a class action Vioxx lawsuit, and a major rating service reiterated that Merck’s outlook is negative.